trial · primary record
Ubamatamab
SMARCB1-Deficient Malignancies
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2028-07-31 |
| Primary endpoint | Safety and adverse events (AEs) |
| Registry ID | NCT06444880 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:43.649Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06444880
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.